The high mutational burden of bladder cancer makes it susceptible to immunotherapy, particularly with checkpoint inhibitors, monoclonal antibodies against programmed cell death-1 (PD-1) and its ligand, PD-L1 [36, 37]. This evidence concerns the gene CD274 and urinary bladder cancer.